Imanova trims Phase I and IIa trial timelines and costs

May 9, 2017 Christoph Graener

Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s Mike Ward how his company can help biotechs and pharma firms cut the cost of Phase I and IIa trials by GBP 2 million (USD 2.6 million) while shaving six months of the time to complete the program. He explains how the company, which was originally GSK’s imaging center and was spun out in 2011, helps clients determine whether a candidate drug gets into the tissue, hits the right target at optimal levels by providing an end-to-end service in PET and MR imaging studies for drug development. Services include experimental design, radio-chemistry, preclinical and clinical imaging, analysis and reporting.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Kevin Cox – CEO, Imanova

 

Previous Article
Producing monoclonals for at least a tenth of the cost

Dutch antibody technology company BiosanaPharma is offering to make monoclonal antibodies at between 5% and...

Next Article
Shanghai Henilus Biotech has blockbuster biologics in biosimilar crosshairs

Dr. Cheni Kwok, a business development and strategy consultant, caught up with Scrip’s Mike Ward to outline...